Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Co-activation of epidermal growth factor receptor and c-MET defines a distinct subset of lung adenocarcinomas.

The American journal of pathology - 1 Nov 2010

Matsubara Daisuke, Ishikawa Shumpei, Sachiko Oguni, Aburatani Hiroyuki, Fukayama Masashi, Niki Toshiro

Abstract excerpt

Epidermal growth factor receptor (EGFR) and MET are molecular targets for lung cancer treatment. The relationships between expression, activation, and gene abnormalities of these two targets are currently unclear. Here, we demonstrate that a panel of 40 lung cancer cell lines could be classified into two groups. Group I was characterized by (1) high phosphorylations of MET and EGFR, (2) frequent mutation or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cisplatin
Share to Enzyme Activation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gefitinib

Share to Paclitaxel

Share to Proto-Oncogene Proteins c-met

Share to Quinazolines

Share to ras Proteins

Share to Receptor, ErbB-2

Source

Open in PubMed Open full text

Identifiers

PMID: 20934974
DOI: 10.2353/ajpath.2010.100217
PMCID: PMC2966779

Genes

MET
EGFR
MUC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Co-activation of epidermal growth factor receptor and c-MET defines a distinct subset of lung adenocarcinomas.PMID 20934974Read ↗

Oncogenic driver mutations in lung cancerSemantic proximity Read ↗

Coexisting EGFR and TP53 Mutations in Lung Adenocarcinoma Patients Are Associated With COMP and ITGB8 Upregulation and Poor PrognosisSemantic proximity Read ↗

EGFR-mutant lung adenocarcinoma harboring co-mutational tumor suppressor genes predicts poor prognosis.Semantic proximity Read ↗

Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations.Semantic proximity Read ↗

Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity.Semantic proximity Read ↗

Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.Semantic proximity Read ↗

Molecular characterization and clinical outcomes in EGFR-mutant de novo MET-overexpressed advanced non-small-cell lung cancer.Semantic proximity Read ↗

Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A ReviewSemantic proximity Read ↗

A gene-alteration profile of human lung cancer cell lines.Semantic proximity Read ↗

EGFR signaling pathway as therapeutic target in human cancers.Semantic proximity Read ↗

Signaling networks assembled by oncogenic EGFR and c-MetSemantic proximity Read ↗

Correlation analysis of mesenchymal-epithelial transition factor protein and human epidermal growth receptor 2 protein expression in 1479 cases of lung adenocarcinoma in China.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.